The median time to treatment initiation across all cancer types increased from 21 days in 2004 to 28 days in 2015. The median time to treatment initiation is increasing across cancer types, and this ...

The FDA expects that randomized, controlled trial data on clinical outcomes will be needed before COVID-19 vaccines can be approved for patients who are 6 months to 64 years of age and do not have ...

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

We need to rethink our approach in responding to cancers in our younger women patients,” said Hope S. Rugo, MD.

The results of our study suggest a concerning pattern in cancer center advertising, particularly among top-ranked institutions,” researchers wrote.

(HealthDay News) — China has promised to give $500 million to the World Health Organization (WHO) over the next 5 years, positioning itself to become the group’s top donor, The Washington Post ...

Our large observational study adds long-term survival to the mounting data supporting the use and safety of conservative surgery for low-risk, early-stage cervical carcinoma,” the researchers wrote.

Some pharmacists worry that tariffs could drive companies out of business while raising prices and creating more drug ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years of age and older and high-risk individuals aged 12-64 years.

Health care data breaches that compromised protected health information more than doubled from 2010 to 2024 in the US, data suggest.

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

The FDA has approved Zynyz (retifanlimab-dlwr) to treat patients with squamous cell carcinoma of the anal canal.